Half-year report · HY
2342.TEDINET S100WYWR
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥13.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥71m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | −¥111m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥83m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥320m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥157m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥57m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥195m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥30m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥182m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥185m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥9.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥10.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.8bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.9bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥4.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥569m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥94m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥421m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥36m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥288m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥175m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥261m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥265m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥379m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥1.77 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-65.51 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-10.97 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 49.8% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.7% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥98m |
| Drug Discovery Support Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥938m |
| Drug Discovery Support Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥935m |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Drug Discovery Support Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥75m |
| Investments And Consulting Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Investments And Consulting Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥62,000 |
| Investments And Consulting Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥245m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥170m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥114m |
| Drug Discovery Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥806m |
| Drug Discovery Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥803m |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| Drug Discovery Support Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥189m |
| Investments And Consulting Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Investments And Consulting Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥45,000 |
| Investments And Consulting Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥192m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 508
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in advances received ope cf | Prior1InterimDuration | 295847000 | JPY |
| Increase decrease in advances received ope cf | InterimDuration | -78967000 | JPY |
| Other net ope cf | Prior1InterimDuration | -52996000 | JPY |
| Other net ope cf | InterimDuration | -89162000 | JPY |
| Subtotal ope cf | Prior1InterimDuration | -444955000 | JPY |
| Subtotal ope cf | InterimDuration | -497546000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1InterimDuration | 305000 | JPY |
| Interest and dividends income received ope cf inv cf | InterimDuration | 1705000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1InterimDuration | -18390000 | JPY |
| Interest expenses paid ope cf fin cf | InterimDuration | -26345000 | JPY |
| Income taxes paid ope cf | Prior1InterimDuration | -57158000 | JPY |
| Income taxes paid ope cf | InterimDuration | -50857000 | JPY |
| Income taxes refund ope cf | Prior1InterimDuration | 99053000 | JPY |
| Income taxes refund ope cf | InterimDuration | 4256000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration | -421145000 | JPY |
| Net cash provided by used in operating activities | InterimDuration | -568787000 | JPY |
| Payments into time deposits inv cf | Prior1InterimDuration | -2040000 | JPY |
| Payments into time deposits inv cf | InterimDuration | -540000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1InterimDuration | -73968000 | JPY |
| Purchase of property plant and equipment inv cf | InterimDuration | -22481000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1InterimDuration | -80382000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | InterimDuration | － | JPY |
| Other net inv cf | Prior1InterimDuration | -18275000 | JPY |
| Other net inv cf | InterimDuration | -12737000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -174666000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -35758000 | JPY |
| Proceeds from issuance of bonds fin cf | Prior1InterimDuration | － | JPY |
| Proceeds from issuance of bonds fin cf | InterimDuration | 50000000 | JPY |
| Redemption of bonds fin cf | Prior1InterimDuration | -7000000 | JPY |
| Redemption of bonds fin cf | InterimDuration | -7000000 | JPY |
| Increase decrease in short term loans payable fin cf | Prior1InterimDuration | 652000000 | JPY |
| Increase decrease in short term loans payable fin cf | InterimDuration | 395000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | 50000000 | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | 120000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -241051000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -272688000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -8583000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -5748000 | JPY |
| Payments for long term accounts payable other fin cf | Prior1InterimDuration | -8067000 | JPY |
| Payments for long term accounts payable other fin cf | InterimDuration | -3418000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | Prior1InterimDuration | -8813000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | InterimDuration | -14688000 | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -49647000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -134000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | 378836000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | 261322000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -4150000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | -323000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -221126000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -343547000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |